The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M HNSCC
Status:
Recruiting
Trial end date:
2026-08-01
Target enrollment:
Participant gender:
Summary
Camrelizumab is an antibody targeting programmed death receptor 1 (PD-1) and its ligand
programmed death-ligand 1 (PD- L1) that is designed to boost the immune system. It does this
by allowing immune cells to fight the cancer. Camrelizumab has been approved by China's
National Medical Products Administration (NMPA) for the treatment of esophageal cancer, liver
cancer and lung cancer. It is currently under study for the treatment of head and neck
squamous cell cancer.